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A B S T R A C TObjective: To assess the cost-effectiveness of early primary total hip
replacement (THR) for functionally independent older adult patients
with osteoarthritis (OA) versus 1) nonsurgical therapy followed by THR
once the patient has progressed to a functionally dependent state
(‘‘delayed THR’’) and 2) nonsurgical therapy alone (‘medical therapy’),
from the Italian National Health Service perspective. Methods: Indi-
vidual patient data and evidence from published literature on disease
progression, economic costs and THR outcomes in OA, including
utilities, perioperative mortality rates, prosthesis survival, and costs
of prostheses, THR, rehabilitation, follow-up, revision, and nonsurgi-
cal management, combined with population life tables, were
synthesized in a Markov model of OA. The model represents the
lifetime experience of a patient cohort following their treatment
choice, discounting costs and benefits (quality-adjusted life-years) at
3% annually. Results: At age 65 years, the incremental cost persee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.10.020
a-Mota@exeter.ac.uk.
ndence to: Rube´n Ernesto Mu´jica Mota, Institute
, Room 104a, Veysey Building, Salmon Pool Lane,quality-adjusted life-year of THR over delayed THR was h987 in men
and h466 in women; the figures for delayed THR versus medical therapy
were h463 and h82, respectively. Among 80-year-olds, early THR is
(extended) dominant. With gradual utility loss after primary THR,
delaying surgery may be more appealing in women than in men in
their 50s, because longer female life expectancy implies longer latter
periods of low health-related quality of life (HRQOL) with early THR.
Conclusions: THR is cost-effective. Patients’ HRQOL benefits forgone
with delayed THR are worth more than the costs it saves to the Italian
National Health Service. This analysis might help to explain women’s
consistently lower HRQOL by the time of primary operation.
Keywords: cost-effectiveness analysis, cost-utility analysis, disease
progression, health-related quality of life, osteoarthritis.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Primary total hip replacement (THR) is considered an effective
and cost-effective treatment to relieve pain and restore physical
functioning and mobility in patients with severe osteoarthritis
(OA) [1]. In spite of the general opinion that patients with OA
should be considered for surgery when other (pharmacological
and nonpharmacological) treatment options provide no ‘‘ade-
quate pain relief and functional improvement’’ [2], no consensus
exists on the disease severity stage at which performing the
operation is optimal [3]. This is reflected, for example, by the
National Institute for Health and Clinical Excellence guidelines,
which recommend that ‘‘referral should be made before there
is prolonged and established functional limitation and severe
pain’’ [4], without providing specific decision criteria. Initial
attempts at developing decision rules to address this issue, using
specific self-reported measures of quality of life, may yet prove to
be of practical use [5].
While there are studies documenting the impact of delaying
surgical treatment on the health status, quality of life [6–8], and
costs [9,10] of eligible patients, no study has evaluated its
implications for cost-effectiveness. Evidence on this issue mayhelp inform doctors’, policymakers’, and health care organiza-
tions’ decisions regarding surgery and its prioritization.
This study investigated the cost and cost-effectiveness of
three options for treating functionally independent patients with
severe OA: 1) primary THR in the first instance, 2) nonsurgical
therapy followed by primary THR upon disease progression to a
functionally dependent state, and 3) nonsurgical therapy with
nonsteroidal anti-inflammatory drugs (NSAIDs). The treatment
decision is analyzed from the perspective of the Italian National
Health Service.Methods
The analytic framework and evidence analyzed were informed by
a literature review on costs and outcomes of THR in OA.
An electronic search in Ovid Medline using the terms ‘‘Osteoar-
thritis,’’ ‘‘Hip Replacement,’’ ‘‘Arthroplasty,’’ and ‘‘Arthrosis’’ com-
bined with ‘‘Costs’’ or ‘‘Outcomes’’ identified the literature in
English published between January 1995 and February 2011 on
clinical events, health-related quality of life (HRQOL), resource
utilization and cost implications of surgery and natural diseaseSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
of Health Service Research, University of Exeter Medical School,
Exeter, Devon EX2 4SG, UK.
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identified studies were also made. Relevant studies on health
outcomes had to have a minimum majority of patients with a
diagnosis of OA, arbitrarily set at 70%, and include elective
surgery patients only. Studies valuing resource use had to refer
to economic costs. The content lists of scientific journals of
health economic evaluation articles written in the Italian lan-
guage were manually searched for studies on costs of THR and
medical therapy, including HTA report catalogues. Relevant
information on study design, population, methodology, and
findings (including effectiveness parameter estimates and costs
and quantities of health care service consumption) was extracted
by using standard record and quality assessment forms.
A Markov model [11] was adapted to describe the experience of a
cohort of functionally independent (American College of Rheuma-
tologists [ACR] class III) patients with severe OA who may undergo
primary THR surgery. The alternative, to remain under nonsurgical
therapy with NSAIDs, involves two mutually exclusive options,
namely, to delay therapy until disease progresses to functional
dependency (ACR class IV) or a lifetime without operation.
Six cohorts defined by sex and age (50–59 years, 60–74 years,
and 75 years and older) with distinct revision risk profiles were
modeled. Transitions occur until 100 years of age, at which pointPrimary unilateral THR 
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Fig. 1 – (A) Markov chain with annual cycles. (B) Markov model
Rheumatologists; OA, osteoarthritis; THR, total hip replacemenremaining cohort survivors are assumed to die. Conditional on
the choice of treatment and an initial age, the model represents
a series of annual contingent transitions to different health
states until death. In each cycle, the patient incurs costs and
accrues benefits according to the state occupied. Benefits are
measured as quality-adjusted life-years (QALYs), whereby each
annual cycle is assigned a utility payoff, a preference-based
valuation of HRQOL in the occupied health state, on a scale
ranging from a negative number (for states worse than death),
including zero (states equivalent to death), to one (representing
full health). Under each treatment option, total benefits and costs
are the sum of QALYs and costs over the modeled life span of the
cohort and are discounted at an annual 3% rate.
Following primary THR, the patient may die (incurring neither
costs nor utility thereafter) as a result of surgery or survive the
operation (‘‘success’’ state). The following year the same person
may experience implant failure, and therefore the need for
revision operation, or remain in the success state. The former
eventuality would be associated with a temporary (1-year period)
deterioration in self-reported HRQOL and an increase in costs of
health care while awaiting revision surgery, which carries an
increased mortality risk (over background general population
mortality risks independent of the health state occupied) (Fig. 1B).Death
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 6 7 – 2 7 9 269Under the nonsurgical option, the patient may be in one of
three states, namely, before progression (i.e., in ACR class III),
after progression to functional dependency (i.e., in ACR IV), or
dead. Disease progression involves additional resource consump-
tion, including increased anti-inflammatory medication and
gastroprotective agent use, additional tests, physiotherapy, and
outpatient clinic visits, and lower utility due to greater limita-
tions on functioning, less physical mobility, and more severe pain
(Fig. 1A).
Using tunnel states the model structure was adapted to
incorporate the option of delayed primary THR, which assumes
that the patient is referred to THR only after the disease has
progressed to a functionally dependent state. Once referred to
THR, the patient faces the same possible risk of death due to
surgery as patients of the same age undergoing surgery in the
first place, although different gains in utility apply, because utility
would have declined with the delay and greater gains are
expected with surgery at lower preoperative utility (although
the level of utility achieved after surgery is lower than that with
immediate THR) [12] (Fig. 1A,B). In this model, delayed THR
implies, on average, an extended period of low HRQOL and
additional drug therapy costs [13] relative to immediate THR, as
well as postponing exposure to the death risk, rehabilitation
disutility, and costs of surgery. Because revision risks are a
function of the age at which primary surgery occurs, delayed
THR may also imply facing a different risk profile to that the
patient would have experienced had the person opted for
immediate surgery.Data
In selecting best-case estimates for parameters, reports most
likely to represent the values of primary THR in the OA patient
population were adopted and other values were used for sensi-
tivity analysis.
Health Events
Estimates of perioperative mortality, postoperative short-term
pulmonary embolism and wound infection for primary and
revision surgery were obtained from large US studies in patients
with OA [14] and the Medicare population [15,16] (Table 1). The
first source was based on more recent, informative data collected
in a representative sample and was therefore used to populate
base-case values. An increased risk of in-hospital mortality from
75 years of age (odds ratio primary: 3.30; revision: 3.96) [14] and a
lower female risk of dislocation in the first 90 days after primary
and revision THR [15,23] (Table 1) were accounted for.
Revision rates for primary and revision procedures were
obtained from the Swedish Hip Arthroplasty Register [18] for all
primary THR operations by sex during 1992 to 2008. Because the
share of OA diagnosis in operations on the youngest subgroup
(40–49 years) was unlikely (at 57% as opposed to 82% in the 50–75
years and 71% in the475 years group) to drive their reported
outcomes [24], this age group was not considered in the analysis.
In the remaining groups, men have a higher rate of revision than
do women (see File I in Supplemental Materials at SI found at
http://dx.doi.org/10.1016/j.jval.2012.10.020). The temporal revi
sion pattern in these Swedish data matches that in the Italian
regional (Emilia Romagna) data with the longest follow-up avail
able (10 years; see File II in Supplemental Materials at SII found at
http://dx.doi.org/10.1016/j.jval.2012.10.020), in spite of different
device fixation practice between the two areas [19,25]. The rate of
repeat revision [20] was assumed constant over time, a simplifica
tion of negligible consequence due to the low revision rate of
primary THR (Table 5 ‘‘Sensitivity Analysis’’).The probability of transition to a more severe, functionally
dependent state was estimated from longitudinal individual
Harris Hip Score (HHS) [26] measurements of patients with OA
on a waiting list for THR in the north of England [20] (I. Wright,
personal communication, November 5, 2010). The analysis (see
File III in Supplementary Materials at SIII found at http://dx.doi.
org/10.1016/j.jval.2012.10.020) yields an estimated annual rate of
0.062 of transition to functional dependence. Alternatively, a
geometric mean annual rate of 0.041 was observed over a
10-year follow-up of patients with hip OA [21]. Both estimates
may be subject to bias; the first is based on a contemporaneous
sample of patients on a waiting list and therefore selective [20];
the second, lower estimate was derived from a historical cohort
at a time when THR was not widespread. They were thus used for
the base-case and sensitivity analysis, respectively.
Utilities
Utilities associated with the annual states in the model are
presented in Table 2, with plausible optimistic (column ‘‘High
THR benefit’’) and conservative (column ‘‘Low THR benefit’’)
parameter values used in sensitivity analyses more and less
favorable to immediate THR. Estimates differentiate by sex, given
women’s lower HRQOL at operation [34] and the negative relation-
ship between preoperative HRQOL and benefit from surgery [12].
Preoperative values, measured by the Euro-Qol five-dimen-
sional (EQ-5D [35]) questionnaire, were adopted for the states
before and after progression under medical therapy and are
consistent with values previously used to represent ACR III and
ACR IV [1]. The corresponding 12-month postoperative values
were used for successful primary THR [27]. The successful
delayed THR state was also assigned this value minus a decre-
ment for the utility loss due to delayed surgery [29]. The
estimated loss was 0.0528, which is the product of the regres-
sion to the mean coefficient between preoperative and post-
operative utility scores of unilateral hip replacement [33] and the
mean difference in preoperative scores between delayed and
early THR (i.e., 0.24 times 0.22; see File IV in the Supplementary
Materials at SIV found at http://dx.doi.org/10.1016/j.jval.2012.10.
020). The base-case values for the need of revision surgery and
successful revision states were taken from preoperative and
postoperative revision hip replacement EQ-5D values [36].
A range of optimistic utility values was considered [28,30,32,
37–39]. Time trade-off values reported from a group of patients
seeing a surgeon for primary and revision operations were used
for consistency across utility parameters [28]. As in the great
majority of studies on utilities, the study did not distinguish
preoperative values by disease severity or level of functional
dependency. Thus, it is assumed that the 0.60 preoperative value
reported by this source corresponds to moderate disease and a
reduction was applied to it to derive the utility for the state of
progression to functional dependency (see File IV in Supplementary
Materials at SIV found at http://dx.doi.org/10.1016/j.jval.2012.10.020).
The conservative value for the utility effect of delaying
surgery adopted in sensitivity analysis was estimated by using
individual patient data on disease status, measured by the HHS,
and utility outcomes [29], recorded with the 15-Dimensional
Utility Index (15D) instrument [40], made available by primary
study authors (P. Rasanen, personal communication, March 4,
2011). The primary THR patient sample was divided between
those with an HHS of 40 to 70 (n ¼ 57) and those with an HHS
of o40 (n ¼ 14), to represent those with ACR III and IV [1], and
obtain the estimates presented in the ‘‘Low gain column’’ of
Table 3, which imply overall, 12-month gains of 0.050 for ACR III
(early THR) and 0.064 for ACR IV (delayed THR). The estimated
gain for revision patients (n ¼ 24) was 0.011. A decline with age
was observed in utility gains from primary surgery, but the
Table 1 – Effectiveness model parameters.
Parameter Value Source
Base case Low High
Primary THR
Perioperative mortality: o75
y
0.0013 0.0012 0.0037 Base case: In-hospital mortality (non–OA- specific — OA:
81% of the sample) [14]
Low: Base case  0.90
Perioperative mortality: Z75
y
0.0042 0.0037 0.0123 High: 90-d rate (non–OA-specific) [15]. Authors’
calculations based on odd ratios (ORs), subgroup
sample sizes, and overall mean estimates [14]
Complications
Pulmonary embolous 0.0068 0.0061 0.0093 Base case: ‘‘Postop. Pulmonary embolism (PE) or deep vein
thrombosis (DVT)’’—OA: 81% of the sample [14]
Low: Base case  0.90
High: 90-d rate of ‘‘PE’’ (non–OA-specific) [15]
Wound infection 0.0005 0.0004 0.0024 Base case: ‘‘Postop. infection’’—OA: 81% of the sample [14]
Low: Base case  0.90
High: 90-d rate of ‘‘wound infection’’ (non–OA-specific)
[15]
Dislocation in men 0.039 0.012 0.049 Base case: 90-d rate of dislocation (non–OA-specific),
female-to-male OR: 0.68 [15]
Low: Female-to-male risk ratio: 2.1 [17]
Dislocation in women 0.027 0.025 0.034 High: Female-to-male risk ratio: 0.93 [16]
Revision rates by sex and age
(50–59 y, 60–75 y, and Z75 y
age groups)
Time varying
discrete hazard
rates in Appendix
None None Primary THR using the annual Swedish report of the Hip
Arthroplasty Register 2008 data, on all diagnoses and all
revision rates in a 17-y follow-up by sex and age for
cemented prostheses [18] in years 1992–2008
Revision hip replacement
Perioperative mortality:
under 75 y
0.0029 0.0026 0.0091 Base case: Revision-specific rates [14]
Low: Base case  0.90
Perioperative mortality: 75þ y 0.0116 0.0104 0.0359 High: Authors’ calculations based on ORs, group sample
sizes, and overall mean estimates [15]
Complications
Pulmonary embolous 0.0108 0.0097 0.0148 Base case: Specific PE rate [14]
Low: Base case  0.90
High: Derived as ratio of low revision to low primary THR
PE values times high value for primary THR PE
Wound infection 0.0025 0.0022 0.0095 Base case: Specific wound infection rate [14]
Low: Base case  0.90
High: [15]
Dislocation in men 0.086 0.029 0.148 Base case: 90-d rate of dislocation (non-OA-specific) [15];
female-to-male OR: 0.95
Low: One third of base case
Dislocation in women 0.082 0.027 0.142 High: 6-mo cumulative dislocation incidence [16]
Repeat revision 0.04 0.036 0.044 [11,19], high/low: 10%
Medical therapy
Natural rate of progression to
functional dependence (i.e.,
ACR III to ACR IV)
0.06 0.04 0.07 Base case: Based on own estimates of transition after 1 y
from primary data [20]
Low: From geometric mean annual rate of transition of a
10-y cumulative incidence of functional dependence
[21]
High: Base case  1.1
All-cause mortality Sex- and age-
specific
None None Base case: Italian National Institute of Statistics (ISTAT)
2008—Italian life tables [22]
ACR, American College of Rheumatologists; OA, osteoarthritis; THR, total hip replacement.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 6 7 – 2 7 9270numbers of the age 75 years or older group (n ¼ 8) were too small
to permit reliable estimation of differences across age groups.
A 3% discount on the utilities for the successful state in the
first year following primary THR and revision hip replacement(RHR) was used to account for the effects of postoperative
rehabilitation on average utility in the year after hip replacement
[49] and assumed the 12-month values to be maintained over the
remaining lifetime in the absence of further hip surgery. This
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Table 2 – Utility values.
State Base case Benefit estimates Tool Source
High THR Low THR
Medical therapy
Utility before progression
(ACR III)
0.52 0.6 0.8 EQ-5D questionnaire Base cas an preoperative value of patients with OA
with ‘‘ ’ reported on the EQ-5D questionnaire
anxiet ression dimension. Value presented is for
men; w n: 0.47 [27]
High: Me eoperative scores elicited from patients with
OA un ing primary THR [28]
Low: Pre tive mean estimates of data from patients
underg THR with 704 HHSZ 40 [29]
High gain: TTO
Low: 15D
Utility after progression
(ACR IV)
0.28 0.39 0.77 EQ-5D questionnaire Base cas an preoperative value of patients with OA
with ‘‘ rate’’ or ‘‘severe’’ reported on the EQ-5D
questi re anxiety/ depression dimension. Value
presen for men; women: 0.25 [27]
High: As d equal to 66% of utility before progression
value [
High: Uti f HHS o 40 [1]
Low: Pre tive utility from patients undergoing THR
with H 40 [29]
High gain: Assumption TTO
Low gain:
15D
Primary THR
Annual successful
primary THR
0.83 0.96 0.86 EQ-5D questionnaire Base cas an postoperative value in patients with
‘‘none’ perative anxiety/depression on the EQ-5D
questi re. Presented value is that for men; the value
for wo is 0.80 [27]
High: Me -mo. postoperative values [28]
Low: Pat undergoing primary THR with
704 H 40 in Finland (value is mean at 12 mo for
age gro –75 y; age 50–59 y, 0.90; age 75þ y, 0.81) [29]
A 3% red n in the values for the first year after
operat applied to account for reduced utility during
rehabi n [31]
High gain: TTO
Low gain: 15D
Preoperative revision hip
replacement
0.35 0.49 0.81 EQ-5D questionnaire Base cas
(Continued on next page)
V
A
L
U
E
I
N
H
E
A
L
T
H
1
6
(
2
0
1
3
)
2
6
7
–
2
7
9
2
7
1sc-
e
n
-
e: Me
none’
y/dep
ome
an pr
dergo
opera
oing
e: Me
mode
onnai
ted is
sume
30]
lity o
opera
HSo
e: Me
’ preo
onnai
men
an 12
ients
HSZ
up 60
uctio
ion is
litatio
e: [32]
Table 2 – continued
State Base case Benefit estimates Tool Source
High THR Low THR
High gain: TTO High: Mean preoperative RHR values [28]
Low gain: 15D
Successful RHR 0.64 0.67 0.82 Low: Mean estimates at 12 mo from data on Finish patients
undergoing RHR [29] (postop utility is mean for age 60–75
y; age 50–59 y, 0.86; age 75þ y, 0.80). A 3% reduction in
the values for the first year after operation is applied to
account for reduced utility during rehabilitation [31]
Delayed THR
Preoperative states ACR
III/IV and revision
states
Same as for
THR
Annual successful
delayed primary THR
0.77 0.85 0.84 Assumption Base: Utility of annual successful THR plus the product of
the regression to the mean coefficient in pre- to
postoperative scores (0.24) in PROMS hip replacement
2011–2012 data set [33] and the difference in utility
between states before and after pregression (0.22).
Value is for men; women, 0.75
EQ-5D questionnaire High: Utility of annual successful THR minus the result of
multiplying the (implicit) regression to the mean from
pre- to 12-mo post operative utility scores [27] by the
difference in medical therapy utility before and after
progression
Low: Mean estimates at 12 mo [29], patients undergoing
primary THR with HHS o 40 in Finland. A reduction of
3% in the values for the first year after operation is
applied to account for reduced utility during
rehabilitation [31]
High: Assumption
TTO
Low:
15D
ACR, American College of Rheumatologists; EQ-5D, EuroQol five-dimensional; 15D, 15-Dimensional Utility Index; HHS, Harris Hip Score; OA, osteoarthritis; PROMS, patient-reported outcome
measures; RHR, revision hip replacement; THR, total hip replacement; TTO, time trade-off.
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Table 3 – Unit costs (annual estimates in 2010 euros).
Cost Mean Lower Upper Source
Primary THR— prosthesis 3272 2370 4173 Mean: Health Basket Project [41]. Additional costs for PE,
dislocations, and deep wound infection complications in the
first year from operation were included
Lower: 33% reduction on base case
Primary THR— other costs 3370 2115 5975 Upper: Prosthesis, highest value in Health Basket sample. Other
costs: Value for 2009 from an orthopaedic hospital in Milan,
based on mean LOS 5.68 and 500–1000 operations
Cost of RHR 8612 5816 29,883 Mean: Primary THR rescaled by 1.3, the ratio of total cost of RHR
to total cost of primary THR [42]. Include costs for operative
complications in the first year
Lower: Imputation for lowest primary THR
Upper: Report for Italian hospital. [43]
Medication use in ‘‘successful’’
state— first year after primary
surgery or revision
182 97 851 Mean/lower/upper: As for ‘‘medical therapy for severe OA,’’
except for proportion of NSAID use: 0.478, where 0.08 at 90% or
more, and rest, 0.398 at (assumed, midpoint) 40% of the year
[13]
Monitoring and rehabilitation the
year after THR
2569 835 3665 Mean: SIOT guidelines for THR [44]. Rehabilitation [45], follow-up
costs of planned visits, imaging x rays, and 40-d regimen of
anticoagulants, physiotherapist visits
Lower/upper: Range of Italian hospital [41]
Medication use in ‘‘successful’’
THR—Secondþ years after
primary
138 74 648 Mean/lower/upper: As in annual cost of medical therapy for
severe OA except for proportion of NSAID use: 0.34, where 0.08
at 90% or more, and rest, 0.26 at (assumed, midpoint) 40% of
the year [13]
Hospitalizations and
physiotherapy—second year after
surgery
384 275 494 Mean: Leardini unpublished data [46]; assumes equal to costs of
hospitalizations before progression times ratio of hospital
costs ACR II to ACR III in RA [47]
Lower/upper: 20% decrease/increase in hospital costs, 50%
decrease/increase in physiotherapy costs
Medical therapy for severe OA 274 147 1285 Mean: NSAIDs consumption, ibuprofen 2.4 g/d, before THR, 90%
and 40% of the year in 21% and 40% of the patients,
respectively [13]; three specialist visits. Includes cost of
gastroprotective agents (GPAs) and preadministration tests
Lower: Nimesulide, 100 mg bid
Upper: Celecoxib, 800 mg/d [48]
Medical therapy for severe OA—with
disease progression
511 274 2393 Mean: NSAIDs use 90% and 40% of the year by 50% of patients
each—assumed
Upper: Celecoxib 400 mg, 2 per day; two outpatient visits
Lower: Nimesulide 100 mg, 2 per day; Higher: Ibuprofen 800 mg,
3 per day [48]y
Hospitalizations and physiotherapy
severe OA
660 463 857 Mean: [46] and unpublished data, imputed on the basis of ratio of
ACR III to ACR II hospital costs in RA [47]
Lower/upper: 20% decrease/increase in hospital costs, 50%
decrease/increase in physiotherapy costs
Hospitalizations and physiotherapy
severe OA— progression
979 662 1296 Mean: [46] and unpublished data, imputed on the basis of ratio of
ACR IV to ACR II hospital costs in RA [47]
Lower/upper: 20% decrease/increase in hospital costs, 50%
decrease/increase in physiotherapy costs
Medical therapy and
hospitalizations and
physiotherapy—Need of revision
934 654 1214 Mean: Assumption same as severe OA under medical therapy
Equal to sum of medical costs (h274) and hospital and
physiotherapy (h660)
Lower/upper: 30%
ACR, American College of Rheumatologists; bid, twice a day; LOS, length of stay; NSAIDs, nonsteroidal anti-inflammatory drugs; OA,
osteoarthritis; PE, pulmonary embolism; RA, rheumatoid arthritis; RHR, revision hip replacement; THR, total hip replacement.
* See main text.
y Includes visits to specialist in proportion to drug use. GPA prophylaxis and treatment costs were derived from costs of NSAIDs and iatrogenic
cost multiplier [46]. Other drugs’ (corticosteroids and analgesics) costs were derived by using the same approach.
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 6 7 – 2 7 9274vely in a sample of 250 patients with OA (mean age 64 years)
undergoing totally cemented and cementless primary THR with
the Mallory-Head implants in the period 1987 to 1992 [38]. (This
figure appears to include both revision free and revision cases,
which represented 10% of the subjects.) The utility payoffs
included the expected disutility due to bleeding ulcer risk [31]
with NSAID consumption [13], although it amounted to less
than 0.01.
Costs
The cost of primary THR was derived from the costs of an
uncomplicated THR operation [41], in five general hospitals with
a range of hospital length of stay for primary THR of 5 to 11 days,
and cementless device use in 60% to 100% of the patients
(Table 3). The cost of RHR was imputed at 1.3 times the costs of
primary THR [50], assuming 14% to be septic operations costing
176% more than revisions due to aseptic loosening [42,43].
The costs of a ‘‘successful’’ THR outcome in the first year after
operation included the costs of routine discharge or inpatient
rehabilitation, follow-up [44,45], and the costs of complications
due to pulmonary embolism and wound infection [51–53] and
dislocations [24,54] up to 30 days postdischarge. Annual costs of
NSAID use and treating and preventing its severe adverse effects
(including medications and diagnostic tests) were calculated on
the basis of anti-inflammatory drug prescription use from the
year before to 2 years post-THR among 28,065 primary care
patients, 95.4% of whom had an OA diagnosis [13]. These costs
were assumed to be proportional to NSAID consumption, for a
total of h182 in the first postoperative year and h138 in subse-
quent years, in line with the documented decline of prescriptions
from the year before to the year after the operation and their
constancy over the second postoperative year [13,46] (see File IV
in Supplementary Materials at SIV found at http://dx.doi.org/10.
1016/j.jval.2012.10.020). Costs of hospitalizations beyond 1 year
postsurgery in the successful primary THR state were assumed
equal to hospitalization costs in the first year times the ratio of
the respective costs in ACR class II (mild OA) to ACR class III
patients [47]. This assumption was subject to sensitivity analysis.
The annual cost of medication use before (h274) and after
(h511) disease progression was derived from NSAIDs’ consump-
tion by patients 1 year prior to surgery [13], at prices of routinely
prescribed cyclo-oxygenase 2 inhibitors and nonselective NSAIDs
[48,55,56]. Costs of treatment and prevention of adverse events
due to the use of NSAIDs, including medications, and tests were
imputed in proportion to costs of NSAIDs [46] (see File IV in
Supplementary Materials at SIV found at http://dx.doi.org/10.
1016/j.jval.2012.10.020). Hospital and physiotherapy costs of
patients with OA [46], adopted for the state before progression
(h660), were multiplied by the ratio of costs of ACR IV to costs of
ACR III patients [47] to derive the figure for the state after
progression (h979). In the absence of medication, hospital, and
physiotherapy costs specific to the state of revision, their values
were assumed to be equal to those under medical therapy before
disease progression, that is, h274 plus h660, and varied by 20%
for sensitivity analysis. Hospital costs were reflated to 2010 by
using the consumer price index for the health sector in Italy [22].
Sensitivity analyses included the costs of care borne by social
services and care paid by households on behalf of functionally
dependent patients (ACR class IV). Among elderly persons
(non–OA-specific) in northern Italy [57,58], those functionally
limited (Guttman scale 1–3 [59]) spent an annual average 2.26
more days in nursing homes than did persons without limita-
tions, amounting to additional costs of h764 (including day care)
to social services and (reflecting extensive availability of
low-paid immigrant, informal labor) of h1691 in costs of paid
home care.Uncertainty Analysis
The effects of variation in individual costs, utilities, and prob-
ability model parameters were examined deterministically. The
effect of extreme values identified in the literature (Tables 1–3)
was assessed by using best-worst case scenarios. Probabilistic
sensitivity analysis was implemented by random sampling from
independent beta distributions [60] for risk of revision [23],
surgical complications [14,15], and disease progression [20]; 12-
month utility gains for primary and revision surgery were
sampled from beta distributions populated by estimates of
the moment equations [61] for the mean and SD [29] (see
File V in Supplementary Material found at http://dx.doi.org/10.
1016/j.jval.2012.10.020).
Cost-Effectiveness Threshold
Thresholds used by previous studies vary from h36,500 to 60,000
[62–64]. Because these values were chosen arbitrarily, the will-
ingness to pay per QALY for the present study was set in proportion
to national income. At 85% of gross domestic product per capita,
i.e., the relative size of the threshold prevailing in England (£20,000/
£23,375) [65], the corresponding threshold in Italy is h22,759.Results
Table 4 presents results for men and women by age at which the
individual first considers the treatment options. The differences
in costs and QALYs between the two THR options and between
delayed THR and medical therapy are presented in the last two
columns of Table 4. Early THR has cost-effectiveness ratios of
h4100 or below in all cases. Across age groups in men, by
targeting surgery to the time disease progresses, delayed THR
saves costs relative to early THR but insufficiently so to compen-
sate the benefit loss, for example, h1991 savings to 3.29 fewer
QALYs at age 50 years. The same pattern is observed among
women, who have lower incremental costs and more QALY
gained with early THR than do men of the same age.
Table 5 presents a univariate sensitivity analysis of the most
influential uncertain parameters. In men, results are driven by
the set of utility values used, and affected to a lower extent by the
nonimplant cost of primary THR and the cost of revision surgery.
Substitution of conservative utility values alters results signifi-
cantly for the oldest patients; in the 80-year-old male case, THR
has incremental cost-effectiveness ratios of early operation of
h20,406 and extendedly dominates delayed surgery. Accounting
for social service costs of care following disease progression
makes surgery more attractive particularly for younger groups.
While discouraging the use of surgery altogether, lowering the
rate of disease progression from 6% to 4% per year also makes
targeting surgery to contingent functionally dependent cases
more economically appealing, as more costs are saved and less
benefit forgone by delayed THR at the lower rate. Other variations
in assumptions not presented in the table resulted in smaller
effects on incremental cost-effectiveness ratio estimates. Similar
variations in results apply to women.
Figure 2A,B present the cost-effectiveness acceptability fron-
tier [61] for 80-year-olds, the group for whom uncertainty in the
cost-effectiveness of THR is highest. The base-case results are
presented on the left panel, and results for conservative utility
gains with other parameters set at base-case values are presented
on the right. The cost-effectiveness probability of early THR rises
with willingness to pay per QALY and more steeply so for women,
due primarily to their lower revision rates and longer
life expectancy (utilities do not play any role as they are the same
for men and women in this analysis). In the base case, early
operation is cost-effective under mild conditions, namely, a
Table 4 – Results: Costs in (h) and benefits by sex and age at point of initial surgery decision.
Age
group
Measure THR Delayed
THR
Medical
therapy
Difference and ICER
THR vs. delayed
THR
Delayed THR vs.
medicaly
Women
Age 80 y Costs 13,404 9,305 7,488 4,099 1,817
QALYs 5.62 3.86 3.08 1.75 0.78
ICER 2,337 2,337
Age 65 y Costs 18,222 16,805 16,591 1,417 215
QALYs 11.59 8.55 5.93 3.04 2.63
ICER 466 82
Age 50 y Costs 24,619 22,887 25,038 1732 2,151
QALYs 16.30 12.83 8.17 3.47 4.66
ICER 499 D
Men
Age 80 y Costs 13,038 8,203 6,384 4,834 1,820
QALYs 4.84 3.29 2.71 1.56 0.58
ICER 3,105 ED
Age 65 y Costs 17,738 15,102 14,147 2,635 955
QALYs 9.95 7.28 5.22 2.67 2.06
ICER 987 463
Age 50 y Costs 23,464 21,472 22,509 1,992 1,037
QALYs 14.81 11.52 7.51 3.29 4.00
ICER 605 D
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; THR, total hip replacement.
* ICER vs. delayed THR unless delayed THR is extended dominated (ED), in which case ratio is relative to medical therapy.
y ICER relative to medical therapy, unless delayed THR is ED by early THR or dominates (has lower costs and more QALYs than) medical
therapy, respectively, labeled ED and D.
Table 5 – Sensitivity analysis: ICER—additional /QALY gained at 2010 prices.
Parameter Age 50 y Age 65 y Age 80 y
THR Delayed
THRy
THR Delayed
THRy
THR Delayed
THRy
Women
Base case 499 D 466 82 2,337 2,337
Conservative utilities (low gain) 2,692 D 2,700 677 15,331 ED
High nonimplant primary THR costs (77%
increase)
972 D 912 612 3,297 ED
High costs of revision 1,783 87 915 336 2,520 ED
Low transition rate (20% reduction) 626 D 672 151 2,693 2,406
High annual discount rate (5%) 852 D 862 328 2,764 2,680
Including nursing home and day-care costs 75 D 68 D 1,899 D
High physiotherapy and hospital costs 695 D 679 311 2,801 2,791
High prosthesis costs (41% increase) 668 D 643 278 2,693 ED
Low drug therapy costs (58% reduction) 688 D 669 439 2,560 ED
Men
Base case 605 D 987 463 3,105 ED
Conservative utilities (low gain) 3,289 D 5,794 3,690 20,406 ED
High other primary THR costs (77% increase) 1,094 190 1,566 1,090 4,210 ED
High costs of revision 1,842 370 1,732 864 3,354 ED
Low transition rate (20% reduction) 761 D 1,205 527 3,445 3,205
High annual discount rate (5%) 987 D 1,366 716 3,475 ED
Including nursing home and day-care costs 159 D 543 D 2,584 D
High physiotherapy and hospital costs 811 D 1,260 726 3,641 ED
High prosthesis costs (41% increase) 768 D 1,202 697 3,483 ED
Low drug therapy costs (58% reduction) 818 99 1,194 821 3,314 ED
* ICER vs. delayed THR unless delayed THR is extended dominated (ED), in which case ratio is relative to medical therapy.
y ICER relative to medical therapy, unless delayed THR is ED by early THR or dominates (has lower costs and more QALYs than) medical
therapy, respectively, labeled, ED and D.
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Fig 2 – Cost-effectiveness acceptability frontiers: (A) Women aged 80 years base case (left) and conservative, low utility gains
(right).  (B) Men aged 80 years base case (left) and conservative, low utility gains (right).  QALY, quality-adjusted life-year; THR,
total hip replacement. From ‘‘Low THR benefit’’ column in Table 3 [29]; other parameters are as for the base-case analysis.
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Fig. 3 – Median (simulated) ICER of early vs. delayed THR,
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 6 7 – 2 7 9276willingness to pay as low as h3,200 per QALY gained. In the
alternative case of conservative utility gains, medical therapy is
the optimal strategy at thresholds below h15,000, whereas early
THR is cost-effective for both genders at thresholds above that
value. It is noteworthy that delayed THR is not cost-effective at
any threshold. The cost-effectiveness of early THR in younger
patients is robust to parameter uncertainty as its willingness-to-
pay constraint is less stringent than those just described for
octogenarians.
One remaining area of uncertainty is the long-term evolution
of utilities. A gradual utility decline in the successful THR state
after the first year postsurgery would increase the appeal of
delayed THR, the more so the younger the patient is at the time of
first needing primary surgery. For example, assuming a 5%
annual rate of utility decline, utility values for women that are
equal to those of men, a low (4%) natural rate of disease
progression, and base-case values for other parameters, delayed
THR in a 50 year old (i.e., an expected median age of operation of
67 years, including a 1-year wait for surgery) would be cost-
effective for women but not for men, who would find early THR
optimal. This apparent contradiction to the earlier findings that
THR is more cost-effective in women than in men is explained by
the fact that women live longer, which, under declining utilities,
implies the prospect of a longer experience of low utility later in
life, avoidable by postponing operation. In this extreme scenario,
delaying operation would not be cost-effective for persons older
than 50 years (see Fig. 3 and File IV in Supplemental Materials at
SVI found at http://dx.doi.org/10.1016/j.jval.2012.10.020).base case at 5% annual utility decline from 12 month onward.
 ICER, incremental cost-effectiveness ratio; THR, total hip
replacement. The utility values for women are set at men’s
values, and values are as for the base case with the exception
that the utility of revision state and successful revision is set
at 61% of the base-case values presented in Table 1 and that
the natural rate of progression is set at the low value of 4% in
Table 1 (see File IV in Supplementary Materials at SIV found
at http://dx.doi.org/10.1016/j.jval.2012.10.020).Discussion
This study found that delayed THR would not be cost-effective at
typical levels of HRQOL of patients undergoing surgery. Only for
patients in their 80s was delaying surgery anywhere near cost-
effective levels of performance, and at the base case 6% annual
rate of disease progression, its corresponding expected time tooperation of 12 years implied that most of these patients would
die before undergoing surgery. The only study that has looked at
a similar issue [8] assessed the optimal time for surgery from the
patient’s perspective and found that postponing surgery for a 62
year old until age 67 years maximized his or her expected QALYs.
In the present analysis, however, delayed THR does not result
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 6 7 – 2 7 9 277in higher QALYs than immediate THR. The main reason for this
discrepancy is that Keren and Pliskin [8] assumed an implant life
expectancy of 15 years, which, given the life expectancy of 20
years for a 62-year-old person in industrialized countries, implies
a high risk of future permanent utility loss from implant failure
following early operation. Indeed, in addition to the risks of
complications from surgery and poor outcomes [66,67], doctors
may not want to operate early because of the cumulative risk of
late prosthetic loosening and need for complex reoperation [3].
Long established patient registry data presented here, however,
and reports from observational studies and other registries
evidence implant survival rates above 90% at 10 years, which
implies that the great majority of 62-year-olds undergoing pri-
mary THR for OA will not experience a revision and suggests the
need to study risk perceptions and preferences of doctors and
their patients.
The insight by Keren and Pliskin [8] may be presented in more
relevant terms. If a 5% annual rate of decline in utility after the
first year postsurgery [28] is applied to this analysis, delayed THR
would become more attractive the younger the patient is at the
time primary surgery is first considered. Moreover, when com-
bined with the longer female life expectancy, it would partly
explain the observation that women are operated later in the
disease course than men [34]. This suggests that the evolution of
utility over the long term is an important source of uncertainty
and merits further research.
While the conclusions are robust, results presented are
sensitive to utility values used. We have adopted the 15-D values
from a study [29] that collected the respective disease severity
scores with HHS, thus enabling delayed THR modeling, and
included elective primary and revision patients. The preoperative
values estimated with this source, based on the 15D tool, are
approximately 60% higher than those based on reports using the
EQ-5D questionnaire [33], with the consequence that estimated
15D gains at 1 year are almost one tenth those in the EQ-5D
questionnaire studies. Besides representing outcomes in a less
severe patient population, the limited scope for gain in 15D
relative to the EQ-5D questionnaire data may reflect a diminished
relative impact of OA on overall utility assessment due to the
additional dimensions measured by the former instrument. The
15D values used in the analysis are consistent with results in the
only other report using this tool to evaluate THR [68].
The model on which this analysis is based relies on a number
of assumptions. The most important is the need to turn to
indirect estimation of relative outcomes for the surgical and
medical treatment options, as a randomized design in this area is
not feasible on ethical principles. Therefore, estimates of model
parameters for costs, probabilities, and utilities have been chosen
to reflect conservative judgments, biased against the surgical
options. Despite limited information on THR costs in Italy and
ability to obtain precise figures, the associated uncertainty is
unlikely to affect the conclusions of this analysis. It must be
noted that the quality of reporting from secondary sources on
revision rates determined the choice of Swedish data for popu-
lating implant survival probabilities. Nevertheless, comparison
with the Italian data with the longest follow-up available (10-
years), which were not available by sex group, suggests that the
pattern of revision in Italy may be adequately represented by the
chosen data.
Revision rates, the only parameter other than the death risk
that varied with age in the model, were assumed to remain
constant from the time of the last available measure—at year 17
after primary THR—onwards. This is a minor limitation because
discounting makes the effect of any bias occurring after such
time negligible. Because no information exists regarding cost
variation by age, the analysis was limited to exploring the
sensitivity of results to 1% increase per year in the cost ofrevision surgery. The conclusions were robust to these variations
(results not shown, available from the author).
The model does not include the possibility of the patient
opting for nonsurgical intervention after failed primary therapy
or revision. However, in a previous similar model analysis [69],
this possibility was considered to have a negligible probability
(o0.01). Although delayed THR operations may be triggered by
factors other than changing clinical status, which was the index
event assumed by the present model, the contribution of other
causes can be approximated by varying the estimated rates of
progression, unit costs, and utilities in the delayed THR option to
reflect a different patient mix in each state at a given time. The
model abstracted from differences across age subgroups in
health utility gain, although the size of the differences observed
in EQ-5D questionnaire scores is not large enough to affect the
conclusions [39]. Another limitation is that the model would be
naturally implemented by a continuous rather than the adopted
discrete time of progression specification, although conclusions
are likely to be robust to such variation.
This study points to further topics for valuable research. The
inclusion of effects of THR on society at large would raise the
cost-effectiveness probability of early operation in younger,
working adults but is hampered by lacking evidence on produc-
tivity costs and patients’ out-of-pocket costs in Italy and else-
where. Medical decision making would benefit from identifying
patient characteristics affecting the rate of disease progression.
Faster radiological and disease progression with older age and
female sex [70,71] would strengthen the case for delaying surgery
in young male patients. However, delaying surgery could carry
significant health risks not captured by this study that are
associated with lack of treatment for limited functioning and
increasingly attract the attention of policymakers [72].
In summary, results suggest that THR is a cost-effective treat-
ment option, and in general should be offered without delay to
functionally independent patients with severe OA. Surgical treat-
ment in octogenarians is supported by the currently available data
as an efficient use of Italian National Health Service resources.
Further evidence is required on the long-term HRQOL and utility of
patients with and without revision, to inform the decision on the
best timing for surgery in patients in their early 50s.Acknowledgments
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